Immix Biopharma in-licenses NXC-201 CAR-T with 71% complete response in multiple myeloma

Immix Biopharma, Inc.

In-licensed exclusive worldwide rights (ex-Israel/Middle East) to NXC-201 (BCMA-targeted CAR-T) from Hadasit and BIRAD.
NXC-201 showed 85% ORR and 71% CR/sCR in 20 relapsed/refractory multiple myeloma patients; 100% ORR and organ response in AL amyloidosis.
Zero neurotoxicity observed; median CRS duration of 2 days at therapeutic dose, supporting potential outpatient use.
Financial terms: $1.5M upfront, $50k annual fee, mid-single digit royalties, up to $20M sales milestones.
Formed wholly-owned subsidiary Nexcella to develop NXC-201; expects minimal impact on Immix financials as Nexcella independently financed.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immix Biopharma, Inc. entered into Research and License Agreement with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. valued at $1,500,000 (effective 2022-12-08).

Action: entry
Agreement: license
Counterparty: Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd.
Value: $1,500,000
Effective: 2022-12-08

Exact text from the filing

On December 8, 2022, Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.) (“Nexcella”), a wholly-owned subsidiary of Immix Biopharma, Inc. (the “Company”) entered into a Research and License Agreement (the “Agreement”) with Hadasit Medical Research Services & Development, Ltd. and BIRAD Research and Development Company Ltd. (collectively, the “Licensors”)

View on SEC.gov

Browse all material agreements →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-035437

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.